PURPOSE:
In the cleft patient, scarring from prior corrective surgeries along with the anatomic aberrancy in the cleft nose leads to poor predictability of nasal changes after midface advancement. Nasal changes in the non-cleft patient after LeFort I advancement is well documented. Those changes are characterized by an increase in alar base width, tip projection, and nasolabial angle. Conversely, the study of nasal changes in cleft orthognathics is limited.
METHODS:
A retrospective chart review was performed of all patients at a single institution who had a cleft lip/palate undergoing LeFort 1 advancement with pre and postoperative 3-dimensional (3D) photos. With 3D imaging software, pre and postoperative measurements were obtained, facilitating both 2D and 3D analysis of nasal changes.
RESULTS:
Nineteen patients (10 girls, 9 boys) met inclusion criteria. Alar base and flare width both increased significantly (1.3mm, p<0.001; 2.3mm, p=0.003), while both total tip projection and relative tip projection decreased (2.0mm, p=0.001, 3.4mm, p<0.001). In addition, 3D analysis of the nose demonstrated an advancement of the entire nasal complex surface postoperatively (1.0mm, p<0.0005). Unilateral cleft patients had a wider alar base following surgery than bilateral clefts (-4.06Â±3.41, -0.98Â±2.15, p=0.032) . On multiple linear regression, presence of a cinch stitch decreases the nasolabial angle (p=0.024), but increases nasal length (p=0.004). Bilateral cleft morphology decreases total tip projection (p=0.024), but increases 3D nasal change (p=0.028).
CONCLUSION:
There are discrepancies in the nasal changes that occur after Lefort I advancement between the cleft and non-cleft population, primarily regarding projection and rotation of the tip. Although the entire nasal surface is advanced postoperatively, tip projection is reduced and rotation limited, potentially indicating scar burden as a significant contributor to changes in nasal aesthetics after cleft orthognathic surgery. 
PURPOSE:
In 2015, deoxycholic acid (DCA) injection was approved for treatment of mild-to-moderate convexity associated with submental fat. The efficacy and safety of submental DCA injection have been demonstrated in four phase 3 randomized controlled trials (RCTs), however, critical assessment of DCA injection in conventional clinical practice is lacking. In a previous report, we presented initial findings from our experience with 100 consecutive patients administered submental DCA. This study describes and evaluates real-world experience with submental DCA injection in a clinical practice setting, and provides an update to our previous report, accounting for additional treatment sessions during long-term follow-up.
METHODS:
This prospective, single-arm, observational study was conducted at a single clinic (private practice) between June 2015 and June 2017. Experience through February 2016 was previously published. The study involved 100 consecutive patients, aged between 18 and 80 years, seeking improvement in convexity/fullness associated with submental fat. Treatment involved DCA injection to the preplatysmal submental fat using an area-adjusted DCA dose of 2 mg/cm 2 , with up to 75 injections (0.2 mL per injection [maximum, 15 mL]) per treatment session for a maximum of 6 sessions. Treatment response was assessed using the clinician-reported submental fat rating scale CR-SMFRS (0 = absent; 1 = mild; 2 = moderate; 3 = severe; and 4 = extreme) and confirmed by independent physician review of photographs at 1 and 5 to 7 weeks posttreatment. Treatment response was defined as an improvement of ≥1 point. AEs, including injection-site AEs such as local edema, numbness, and tenderness were monitored at each followup visit. Patient demographics, response, and safety were compared between patients who underwent single versus multiple treatment sessions.
RESULTS:
Since the prior published report, 17 patients have undergone additional treatment sessions. Overall, one hundred patients have had 195 treatment sessions: 41, 36, 14, 6, 2, and 1 patient had 1, 2, 3, 4, 5, and 6 sessions, respectively. In the multiple-treatment-session (MTS) group, most (36/59 [61.0%]) patients had 2 sessions; 14 (23.7%) had 3 sessions, 6 (10.2%) had 4 sessions, 2 (3.4%) had 5 sessions, and 1 (1.7%) had 6 sessions. A mean (SD) of 6.7 (2.3) mL of DCA was administered per treatment session, with significantly more DCA administered to the MTS than singletreatment-session (STS) group (6.8 [2.3] vs 6.1 [2.2] mL/ session; p = .049). Overall, 33 of 36 (91.7%) patients in the STS group and all 59 (100.0%) patients in the MTS group had an improved CR-SMFRS score by ≥1 point. Local edema, numbness, and tenderness were reported for a mean (SD) of 7.1 (5.1), 27.9 (11.3), and 3.5 (3.5) days post-treatment, respectively.
